The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma

E. Fenig*, H. Lurie, A. Sulkes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Five patients with advanced Merkel cell carcinoma (MCC) are described. Four patients with regional lymph node involvement and one with disseminated skin metastases were treated with systemic chemotherapy, including cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). The patients received a median of six cycles of CMF (range: 2 to 6), and chemotherapy was well tolerated. Four complete and one partial response were noted. Three patients are alive and are disease-free at 5, 12, and 37 months from the onset of CMF chemotherapy. Two patients died from disseminated metastatic disease at 3 and 24 months from the onset of chemotherapy. CMF chemotherapy appears to be an active regimen in the treatment of locally advanced MCC. Further experience with this combination is warranted.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma'. Together they form a unique fingerprint.

Cite this